Evidence map›Paper›PMID 30069645›Full record

ArticleEJNMMI research2018

[

Per Stenkrona, Granville J Matheson, Simon Cervenka, Pontus Plavén Sigray, Christer Halldin, Lars Farde

Abstract read
In one paragraph

Article in EJNMMI research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. D1-Dopamine Receptor Availability in First-Episode Neuroleptic Naive Psychosis Patients.The international journal of neuropsychopharmacology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Per StenkronaDepartment of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska University Hospital, Karolinska Institutet, R5:02, S-171 76, Stockholm, Sweden. per.stenkrona@ki.se.ORCID http://orcid.org/0000-0002-5529-3336
Granville J MathesonDepartment of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska University Hospital, Karolinska Institutet, R5:02, S-171 76, Stockholm, Sweden.
Simon CervenkaDepartment of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska University Hospital, Karolinska Institutet, R5:02, S-171 76, Stockholm, Sweden.
Pontus Plavén SigrayDepartment of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska University Hospital, Karolinska Institutet, R5:02, S-171 76, Stockholm, Sweden.
Christer HalldinDepartment of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska University Hospital, Karolinska Institutet, R5:02, S-171 76, Stockholm, Sweden.
Lars FardePET Science Centre, Precision Medicine and Genomics, IMED Biotech Unit, AstraZeneca, Karolinska Institutet, Stockholm, Sweden.

Funding

Vetenskapsrådet 2015-02398
6 · The paper itself

Abstract

backgroundThe D

methodsFifteen healthy subjects underwent two PET measurements with [

resultsAutomated target region delineation produced lower BP

conclusionsThe results suggest that the choice of ROI delineation method is not an important factor for reliability, whereas the improved results following movement correction confirm its importance in PET image analysis. Realignment is therefore especially important for measurements in patient populations such as schizophrenia or Parkinson's disease, where motion artifacts may be more prevalent.

Indexed as

D1-dopamine receptorFreeSurferPositron emission tomographyRealignmentROI

Identifiers

PMID30069645
PMCPMC6070454

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.